Practical Considerations for Demonstrating Drug Substance Uniformity - The authors describe considerations and best practices for meeting drug substance uniformity. - BioPharm International


Practical Considerations for Demonstrating Drug Substance Uniformity
The authors describe considerations and best practices for meeting drug substance uniformity.

BioPharm International
Volume 24, Issue 4, pp. 30-37


Figure 1: Flow diagram of drug substance filtration. (FIGURE IS COURTESY OF THE AUTHOR)
The DS specification parameters for biological products confirm the identity, purity, potency, quality and safety of the API. The ultimate aim of a DS uniformity study is to ensure that individual DS containers are consistent with respect to all of these critical quality attributes (CQAs) or specification parameters. For the purpose of demonstrating uniformity, it is not necessary to test each of the DS specification parameters, since a subset of the parameters may be used as a surrogate for the others. Typically, the quantitative specification parameters can be used to demonstrate uniformity. Representative assays may include protein concentration by absorbance (e.g., UV280), high performance liquid chromatography (HPLC) or bioassay. Of these, the UV280 is the simplest and fastest measurement with an acceptable degree of accuracy and precision. Protein concentration also allows evaluation of possible mechanisms for introduction of non-uniformity to the DS batch (e.g., dilution due to residual flush liquid, protein adsorption to the filter material, or inherent uniformity challenges with the upstream pool). Other parameters, such as pH, osmolality, conductivity and/or purity (e.g., aggregate concentration) may also be used as measures for DS uniformity. It is important to consider the potential failure modes for uniformity when selecting performance parameters such that they are sensitive enough to pick up a lack of uniformity. For example, if dilution with residual water is a potential source for non-uniformity, pH may not be the best parameter to use because water for injection (WFI) may not significantly impact the buffering capacity of the drug substance formulation buffer. Additionally, stabilizing agents such as polysorbate may be a critical component of the DS and it may be necessary to demonstrate that the concentration of such agents is within required limits. Other factors, such as shear could impact DS product quality (particle size, aggregation, potency), and a risk assessment should be considered to identify and mitigate these potential outcomes. Validation provides evidence of sufficient uniformity such that any sample location across the fill is representative of the entire DS lot with respect to the CQAs. Validation allows batch release and stability testing to be performed on a representative sample collected from a single location within the DS fill operation.

Another key question is when to take the samples to demonstrate uniformity and how to establish appropriate validation acceptance criteria. Typically, samples may be taken at the beginning, middle, and end of bulk filtration, and if they meet prospective acceptance criteria, the entire batch can be considered to be homogenous. The sample collection strategy is an important consideration: Does one take a point sample (i.e. directly from the filter bell), or a pool sample from the actual container? The latter is more relevant but needs to be balanced against the potential risk of contamination during sampling, and mixing considerations prior to taking the sample. Typically, the beginning sample is taken as a pool sample from the first container, as this reflects how the contents of the DS will be forward processed. If the DS lot-release and stability samples are taken as point samples at the middle of bulk filtration, the use of point samples during a uniformity study may be favorable for consistency and to minimize potential for contamination.

There are several ways to establish acceptance criteria to demonstrate DS uniformity, which may be used in isolation or in combination, as appropriate. Prior to selecting a preferred strategy, it is important to understand how the DS will be used during the subsequent DP formulation and testing, and to ensure that the requirements for these steps are addressed in the DS approach. Several methods for DS testing, and their pros and cons, are briefly discussed below.

Calculation based on DP specification limits

This method is based on a back calculation of the requirements for DP processing and DP specification criteria. The DS batch may be divided and used over several DP batches. In order to maintain this flexibility, it is necessary to ensure that any DS batch or part thereof used for DP processing will meet the DP specification requirements. It is necessary to take into account the smallest DP stock keeping unit (SKU), including product concentration and manufacturing volume, which will be used. The advantage of this method is that it is based on processing needs. However, it may be complicated by the existence of multiple SKUs and the desired safety margin between a passing uniformity result for DS compared to the associated specification range for DP.

blog comments powered by Disqus



Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
PDA Announces Technical Report on Drug Shortages
September 9, 2014
European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
FDA Releases Guidance Electronic Submission of Lot Distribution Reports
September 5, 2014
Infinity and AbbVie Collaborate to Develop Oncology Drug
September 5, 2014
Author Guidelines
Source: BioPharm International,
Click here